Elan to shutter 104-employee PA facility; Eisai to market Orion products in China;

@FiercePharma: Note to Pfizer: Bayer shopping for vet buys. Article | Follow @FiercePharma

> Elan is eliminating 104 jobs from a Pennsylvania facility that is part of the $960 million sale of its drug delivery unit to Alkermes deal. The facility is expected to be closed by September, the company tells Pharmalot. News

> Eisai has linked up with Orion to sell two of the Finnish drugmaker's breast cancer and Parkinson's disease treatments in China. Item

> Teva Pharmaceutical Industries completed its acquisition of Taiyo Pharmaceutical for $934 million in cash. Story

> Nigeria's second-largest drugmaker, May & Baker, plans to start exports to western and central Africa before the end of this year, CEO Nnamdi Okafor said. Article

> U.K. primary care trusts are not slashing the drugs budget as a cost-cutting move under the NHS' quality, innovation, productivity and prevention program, a leading official has told PharmaTimes. News

> Skin treatments supplier Sinclair IS Pharma said full year revenue raced ahead of expectations last year due to a strong performance in its fourth quarter and the contribution of its newly merged business. Report

Biotech News

@FierceBiotech: J&J's success with Hep C partners might hit a snag. Story | Follow @FierceBiotech

> Bristol-Myers grabs EU approval of key melanoma drug. Article 

> DVS Sciences lands $14.5M round with Big Pharma support. Report

> Verastem snags $32M for drugs against cancer stem cells. Item 

Manufacturing News

> Indian pharmas seek to protect their edge Report

> Corpedia, Second City bring comedy to compliance training. Item

> Hamburg appoints FDA deputies; Spielberg oversees drugs. Report 

> GSK's Witty: West can compete in manufacturing. Story 

> Pew track/trace call highlights congressional dallying. News  

> Expert: Boost audit programs to keep up with outsourcing More

Vaccines News

> With Gates Foundation backing, Liquidia advances novel flu vaccine. Item

> Shingles vaccination levels fall short of expectations. Report

> Crucell and Scripps find antibody for universal flu vax. News

> The CIA, bin Laden and the future of vaccine programs. Story

> GSK gets Boostrix approval for adults over 65. Article

> Microneedles may be better for H1N1 delivery. More

And Finally... People who regularly drink tea or coffee may be less likely to be carriers of the "superbug" MRSA, according to a U.S. study. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.